Navigation Links
DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA
Date:5/4/2009

Exclusive distribution agreement in place with GE Healthcare

NOIDA, India, May 4 /PRNewswire/ - Jubilant Organosys Ltd, headquartered in India, announced today that its subsidiary in the United States, DRAXIMAGE LLC has received US Food and Drug Administration (FDA) approval for the Company's Abbreviated New Drug Application (ANDA) for DRAXIMAGE(R)'s generic Sestamibi. The product is found to be bioequivalent and therapeutically equivalent to reference listed drug Cardiolite(R).

DRAXIMAGE(R) Sestamibi, is a generic kit used in the preparation of Technetium (Tc-99m) Sestamibi injection - a diagnostic cardiac imaging agent used in Myocardial Perfusion Imaging (MPI), to evaluate the flow of blood to the heart. The MPI market size is currently estimated at USD 400 million.

Jubilant, through its subsidiary in the US, has an exclusive distribution agreement with GE Healthcare to distribute and sell DRAXIMAGE(R)'s generic Sestamibi through GE Healthcare's nuclear pharmacy network in the US.

Commenting on the development, Shyam S. Bhartia, Chairman, and Hari S. Bhartia, Co-Chairman of Jubilant Organosys said: "We are very excited to receive the USFDA approval of one of our key radiopharma products which strengthens our position in this business. We are ready to launch DRAXIMAGE(R) Sestamibi in the market and will see a steady flow of revenues from this product from Q1 FY10. As we are the second generic player in the market and there is very limited competition,we expect moderate price erosion for this product."

The DRAXIMAGE(R)'s generic Sestamibi USFDA approval is a significant milestone for the Company's radiopharma business. Along with the earlier approvals in Canada and distribution agreement with Guerbet for Europe, the Company is well positioned to capture a significant market share for this product in the regulated markets. Going forward the Company plans to introduce this product in the Asian markets, Australia and rest of the world.

GE Healthcare is regarded as a strong player in the nuclear medicine market. It has a very strong network of nuclear pharmacies across the US with a considerable market share in the MPI segment.

DRAXIMAGE(R) Sestamibi is the only generic Tc-99m for MPI, to be marketed by GE, thus complementing GE's product and service offerings to their customers. The initial term of the distribution agreement is for a minimum of three years post approvals and the product is expected to be launched shortly.

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

For more information: visit www.jubl.com

About Draximage

DRAXIMAGE, develops, manufactures and markets diagnostic and therapeutic radiopharmaceuticals for the global nuclear medicine marketplace.

Products include a proprietary line of lyophilized technetium-99m kits (MAA, MDP, DTPA and Sestamibi) used in several medical imaging procedures. DRAXIMAGE is also a leading supplier of I-131 radiopharmaceuticals in North America, used for the diagnosis and treatment of thyroid disorder and cancer. Products in development comprises "next generation" Rubidium-82 and Technicium-99m generators. DRAXIMAGE products are exported worldwide, with regulatory approval in USA, Canada, parts of Europe and South-East Asia.

For more information: visit www.draximage.com

Cardiolite(R) is a registered trademark of Lantheus Medical Imaging

Disclaimer:

-----------

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.


'/>"/>
SOURCE DRAXIS Specialty Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Generic prostate drug helps find high-risk cancers early
7. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
9. FDA Announces Initiative to Bolster Generic Drug Program
10. FDA Struggles to Keep Pace With Requests for Generics
11. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Medicine will have the unique opportunity to get hands-on experience in an ... school students an immersive experience to gain invaluable, real-life medical skills that are ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry ... Control through a new partnership with Splashtop Inc. This remote control for Android ... to help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
(Date:12/8/2016)... Dec. 8, 2016  A new study by a ... use of opioid therapy to treat chronic pain is ... of more harmful consequences, including death. Palliative ... Zankhana Mehta , M.D., authored the study which ... opioid therapy. The study was published in the December ...
(Date:12/8/2016)... -- Mederi Therapeutics Inc . hat die behördliche Zulassung durch die ... Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the ... at Wuhan Union Hospital ...
Breaking Medicine Technology: